Back HIV/AIDS HIV/AIDS Topics HIV Prevention

More iPrEx and OLE Data Published: Adherence Higher in U.S.

Participants enrolled at the U.S. study sites of the global iPrEx trial of Truvada pre-exposure prophylaxis (PrEP) achieved better adherence than those in other countries, reaching 90% in San Francisco, researchers reported in the September 16 advance edition of Journal of Acquired Immune Deficiency Syndromes. Findings from the iPrEx open-label extension (OLE) were also recently published.

alt

Read more:

Many HIV Infections Among Gay Men May Be Related to Condom Failure

About half of all new HIV infections among men who have sex with men in Canada may occur during anal sex with a condom, suggesting that condom failure is more common than previously recognized, according to a report in the September 11 edition of PLoS ONE.

alt

Read more:

ICAAC 2014: Tenofovir Vaginal Ring and Nanoparticle Gel Are Protective in Animal Studies

A vaginal ring that dispenses tenofovir protected all 6 macaque monkeys exposed to an HIV-like virus, while a heat-sensitive vaginal gel containing tenofovir nanoparticles prevented infection of mice, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

alt

Read more:

PrEP Rally: As Numbers Rise, Advocates Want Wider Access

The number of people using pre-exposure prophylaxis, or PrEP, to prevent HIV infection has risen steadily over the past year, according to data presented this week at a San Francisco community engagement forum. But PrEP advocates -- including 3 city supervisors -- say more needs to be done to overcome barriers to access for all who want it.

alt

Read more:

PrEP by the Numbers: Interpreting Conflicting Study Data

A recent ad campaign from the AIDS Healthcare Foundation has kicked of a new round of controversy about HIV pre-exposure prophylaxis (PrEP) and how to interpret apparently conflicting numbers from prevention studies.

alt

Read more: